研究 CA239-0006 是一项开放标签、随机第三期临床试验，比较 MRTX849 联合 cetuximab 与化疗在 KRAS G12C 突变结直肠癌患者第二线治疗中的疗效。
适应症：Advanced Colorectal Cancer、Metastatic Colorectal Cancer
入组条件
纳入标准
- Histologically confirmed diagnosis of colorectal carcinoma with KRAS G12C mutation in tumor tissue.
- Prior receipt of 1st line treatment in advanced CRC with a fluoropyrimidine-based chemotherapy regimen containing either oxaliplatin or irinotecan, and radiographically documented progression of disease on or after treatment.
排除标准
- Prior treatment with a therapy targeting KRAS G12C mutation (e.g., AMG 510).
- Prior treatment with an anti-EGFR antibody (e.g., cetuximab or panitumumab).
- Active brain metastasis
入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年10月8日。